Pretarget lymphoma therapy

Drug Profile

Pretarget lymphoma therapy

Alternative Names: Pretarget technology

Latest Information Update: 07 Apr 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Poniard Pharmaceuticals
  • Class Antibodies
  • Mechanism of Action CD20 antigen inhibitors; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma

Most Recent Events

  • 07 Apr 2004 NeoRx's Pretarget® technology has been licensed to Aletheon Pharmaceuticals worldwide
  • 24 Jul 2002 Discontinued - Phase-I for Non-Hodgkin's lymphoma in USA (unspecified route)
  • 25 Jun 2002 A phase I study has been added to the adverse events and Cancer therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top